RTSL (Rapid Therapeutic Science Laboratories) EBIT: $0.65 Mil (TTM As of Jun. 2023)


What is Rapid Therapeutic Science Laboratories EBIT?

Rapid Therapeutic Science Laboratories RTSL EBIT is $0.65 Mil as of Jun. 2023.

Rapid Therapeutic Science Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2023 was $0.11 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.65 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Rapid Therapeutic Science Laboratories's annualized ROC % for the quarter that ended in Jun. 2023 was -7.85%. Rapid Therapeutic Science Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 26.75%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Rapid Therapeutic Science Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 32,400.00%.

Rapid Therapeutic Science Laboratories  (OTCPK:RTSL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Rapid Therapeutic Science Laboratories's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2023 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-0.416 * ( 1 - 0% )/( (5.362 + 5.238)/ 2 )
=-0.416/5.3
=-7.85 %

where

Invested Capital(Q: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.034 - 0.884 - ( 0.018 - max(0, 4.463 - 0.251+0.018))
=5.362

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.074 - 0.944 - ( 0.002 - max(0, 4.426 - 0.318+0.002))
=5.238

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Rapid Therapeutic Science Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2023  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.428/( ( (1.614 + max(-0.863, 0)) + (1.586 + max(-0.795, 0)) )/ 2 )
=0.428/( ( 1.614 + 1.586 )/ 2 )
=0.428/1.6
=26.75 %

where Working Capital is:

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.175 + 0.058) - (0.884 + 0 + 0.212)
=-0.863

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.175 + 0.058) - (0.944 + 0 + 0.084)
=-0.795

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Rapid Therapeutic Science Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2023 )
=0.648/0.002
=32,400.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Therapeutic Science Laboratories EBIT Related Terms

Rapid Therapeutic Science Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for Rapid Therapeutic Science Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Therapeutic Science Laboratories EBIT Chart

Rapid Therapeutic Science Laboratories Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.52 -0.17 -0.43 -1.54 0.10

Rapid Therapeutic Science Laboratories Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.12 0.12 0.30 0.11

RTSL vs VRAYQ, NNMX, ABT: EBIT Comparison

For the Shell Companies subindustry, Rapid Therapeutic Science Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Therapeutic Science Laboratories EV-to-EBIT vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Rapid Therapeutic Science Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Rapid Therapeutic Science Laboratories's EV-to-EBIT falls into.


Rapid Therapeutic Science Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $0.65 Mil mean?
Rapid Therapeutic Science Laboratories (RTSL) has a EBIT of $0.65 Mil as of Jun. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Rapid Therapeutic Science Laboratories.
Is Rapid Therapeutic Science Laboratories' EBIT too high?
Rapid Therapeutic Science Laboratories' current EBIT is $0.65 Mil.
How does Rapid Therapeutic Science Laboratories' EBIT compare to VRAYQ and NNMX?
Rapid Therapeutic Science Laboratories' EBIT of $0.65 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Diversified Financial Services company?
A good EBIT depends on the Diversified Financial Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Rapid Therapeutic Science Laboratories. Rapid Therapeutic Science Laboratories's current EBIT is $0.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Therapeutic Science Laboratories stock overvalued right now?
Rapid Therapeutic Science Laboratories (RTSL) has a current EBIT of $0.65 Mil. The current EBIT is $0.65 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Rapid Therapeutic Science Laboratories (RTSL), the current EBIT is $0.65 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapid Therapeutic Science Laboratories Business Description

Address 558 County Road 472, De Leon, TX, USA, 76444
Rapid Therapeutic Science Laboratories Inc currently has no operations and operates as a blank check company.